PHILADELPHIA, March 31, 2025 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company") today announced that its Board of Directors has approved a revised operating plan ...
PHILADELPHIA, Nov. 17, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing ...
Carisma Therapeutics, Inc., a biotechnology company, focuses on developing transformative therapies to treat liver fibrosis and cancer in the United States. Its product candidates include CT-2401, ...
Carisma Therapeutics had already laid off 95% of its team earlier this year. Now, a Hail Mary merger proposal with another biotech has fallen through. The cell therapy macrophage biotech had just six ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
During hip-hop's golden era, DJs played a pivotal role in fueling the culture. As the preeminent voices of authority, breaking songs and introducing acts to the mainstream, being a DJ demanded far ...
Building on successful pre-clinical in vivo CAR-M data in oncology, the companies will develop in vivo CAR-M for autoimmune diseases Under this expanded collaboration, Carisma and Moderna will ...
For the second time this year, Carisma is laying off staff. The newly announced restructure includes several company leaders hitting the exit and the discontinuation of the biotech’s sole clinical ...
Evercore ISI downgraded Carisma Therapeutics (CARM) to In Line from Outperform with a price target of 70c, down from $4. With its second major pipeline shift this year, Carisma is focusing on in vivo ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results